NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced that its Chief Scientific Officer, Dr. Dennis Hruby, will be presenting information regarding the company’s progress in developing its lead drug candidate, ST-246, to the WHO Advisory Committee on Variola Virus Research on November 28, 2007 in Geneva, Switzerland.
